October 18, 2011: Boulder, CO-based miRagen has racked up its first big collaboration, inking a development pact with France’s Servier for two of its top preclinical programs as well as a third, as yet unidentified, program. In exchange for commercialization rights outside the U.S. and Japan, miRagen gets $45 million in an upfront payment, research support and near-term milestones, up to $352 million in total milestones and double-digit royalties on approved products. [click here for more information]…

April 7, 2011: CardiaLen, Inc. is pleased to announce that it was notified by the National Heart, Lung, and Blood Institute of a $216,027 Phase I SBIR award to develop an enhanced system for atrial defibrillation (AF). [click here for more info]…

March 29, 2011: CardiaLen, Inc., a medical device company focused on providing pain-free internal cardioversion therapy for atrial fibrillation (AF) with a low-energy implantable atrial cardioverter plus pacing device, received $735,000 in funding from Broadview Ventures, Inc. [click here for more info]…

January 7, 2011: CardiAQ Valve Technologies (CVT), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), today announced that it has appointed Rob Michiels as Chief Executive Officer (CEO), effective immediately.  Mr. Michiels will remain as a Director of CVT. [click here for more info]…